Advances in neuroimaging and genomics provide an unprecedented opportunity to accelerate medication development for nicotine dependence and other addictions. Neuroimaging studies have begun to elucidate the functional neuroanatomy and neurochemistry underlying effects of nicotine and nicotine abstinence. In parallel, genetic studies, including both candidate gene and genome-wide association approaches, are identifying key neurobiological targets and pathways important in addiction to nicotine. To date, only a few neuroimaging studies have explored effects of nicotine or abstinence on brain activity as a function of genotype. Most analyses of genotype are retrospective, resulting in small sample sizes for testing effects of the minor alleles for candidate genes. The purpose of this review is to provide an outline of the work in neuroimaging, genetics, and nicotine dependence, and to explore the potential for increased integration of these approaches to improve nicotine dependence treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600518 | PMC |
| http://dx.doi.org/10.1016/j.bbr.2008.05.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nicotine Dependence Comorbid with Depressive Symptoms May Limit Immediate Cognitive Improvement Following Exercise.
Physiol Behav
January 2025
Department of Physical Education, Pusan National University, Busan, Republic of Korea. Electronic address:
This study investigated how acute bouts of aerobic exercise versus yoga affect inhibitory control differently in smokers with nicotine dependence depending on the presence of depressive symptoms. Thirty adult smokers were equally divided into a depressed smoker group and a non-depressed smoker group based on their Beck Depression Inventory scores. Each participant underwent baseline measurements, a 30-minute aerobic exercise session, and a 30-minute yoga session on different days.
View Article and Find Full Text PDFPharmacological treatment for substance use disorder: A systematic review.
Addict Behav
January 2025
Faculty of Health Sciences. Valencian International University. Valencia, Spain. Electronic address:
Introduction: There is strong evidence of the substance dependence has a negative impact on key dimensions of health. The scientific evidence suggests that pharmacological treatment could play a fundamental role in its clinical management.
Objective: The aim of this systematic review is to explore the existing pharmacological options for the treatment of substance use disorders.
Predictors of Participation in Prenatal Substance Use Assessment, Counseling, and Treatment Among Pregnant Individuals in Prenatal Settings Who Use Cannabis.
J Addict Med
November 2024
From the, Kaiser Permanente Washington Health Research Institute, Seattle, WA (GTL); Department of Health Systems and Population Health, University of Washington, Seattle, WA (GTL); Division of Research, Kaiser Permanente Northern California, Oakland, CA (FWC, KCY-W, MBD, CIC); Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA (KCY-W, CIC); and Regional Offices, Kaiser Permanente Northern California, Oakland CA (DA, CC, AHA, AE).
Objectives: Assessment and counseling are recommended for individuals with prenatal cannabis use. We examined characteristics that predict prenatal substance use assessment and counseling among individuals who screened positive for prenatal cannabis use in prenatal settings.
Methods: Electronic health record data from Kaiser Permanente Northern California's Early Start perinatal substance use screening, assessment, and counseling program was used to identify individuals with ≥1 pregnancies positive for prenatal cannabis use.
Genome-wide association study of varenicline-aided smoking cessation.
Nicotine Tob Res
January 2025
Department of Population Health Sciences, University of Leicester, Leicester, UK.
Introduction: Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist with the highest therapeutic efficacy of any pharmacological smoking cessation aid and a 12-month cessation rate of 26%. Genetic variation may be associated with varenicline response, but to date no genome-wide association studies of varenicline response have been published.
Methods: In this study, we investigated the genetic contribution to varenicline effectiveness using two electronic health record-derived phenotypes.
Smoking History and Nicotine Dependence Alter Sleep Features in Patients with Obstructive Sleep Apnea-Hypopnea Syndrome.
Healthcare (Basel)
December 2024
Respiratory Failure Clinic and Sleep Laboratory, General Hospital of Thessaloniki "G. Papanikolaou", Aristotle's University of Thessaloniki, 541 24 Thessaloniki, Greece.
There are many aspects in the relationship between smoking and sleep that have not been investigated thoroughly yet, especially in regards to obstructive sleep apnea-hypopnea syndrome (OSAHS). In this cross-sectional study, 2359 participants, who have visited the sleep clinic of our hospital during a 13-year period and were former or current smokers, were included. Their smoking history, measured in packyears of smoking, and their nicotine dependence, measured with the Fagerström scale, were correlated with various epidemiological and sleep-related variables.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!